title: Safety of cefotaxime and other new beta-lactam antibiotics.
abstract: beta-Lactam antimicrobial agents have until recently enjoyed a reputation of reliability and safety. Now serious problems have emerged associated with use of some of the newer drugs of this class. Latamoxef (moxalactam) and cefoperazone, both of which have a methyltetrazolethiol side chain, have been reported to cause coagulation abnormalities, clinical bleeding, and disulfiram-like reactions. In addition, an unusually high incidence of diarrhoea has been associated with administration of cefoperazone. Cefotaxime does not have the [methylthiotetrazole] side chain and has not caused bleeding, coagulopathy, or disulfiram-like reactions. Diarrhoea, usually mild, has been observed in only 1% of patients given cefotaxime in clinical trials. The remarkable safety record of cefotaxime is an important consideration for clinicians in the selection of an antimicrobial agent for seriously ill patients.
mesh_terms: D000900:Anti-Bacterial Agents / Q000633:toxicity*; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D002439:Cefotaxime / Q000633:toxicity*; D003967:Diarrhea / Q000139:chemically induced; D004221:Disulfiram / Q000009:adverse effects; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents; D002439:Cefotaxime; D004221:Disulfiram